BIOXYTRAN, INC. (BIXT), a developmental stage biot
Post# of 101
(Total Views: 254)
Posted On: 04/05/2019 1:35:02 PM
BIOXYTRAN, INC. (BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Company has entered into a definitive exclusive licensing agreement with MDX Lifesciences, Inc. (MDX). The licensing agreement will allow Bioxytran to continue commercial development of MDX technology and develop new protocols that measure the tissue metabolic state of the brain.
(0)
(0)Bioxytran, Inc. (BIXT) Stock Research Links
Scroll down for more posts ▼